Skip to content
DataLookout
Start free
Menu

NCT07216079

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

StatusActive, Not Recruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 7 words
    • Final enrollment: 3 participants (planned 4)
    • Primary and study completion dates: Nov 30, 2026 to Nov 25, 2026
  2. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 3
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

AEs including SAEs and AESIs
Timeframe: Until study completion, approximately 60 weeks

Arms and interventions

RilzabrutinibExperimental

400 mg

Drugs: rilzabrutinib

Sites

3 sites in 1 country